FREMONT, Calif., March 8, 2017 /PRNewswire/ -- BioGenex, a global leader in molecular pathology announced introduction of monoclonal antibodies for the detection of immune checkpoint proteins: PD1 and PD-L1 by immunohistochemistry (IHC). The antibodies are CE marked and are also available for purchase in the US. The PD1 and PD-L1 antibodies can be used to determine the expression status of the target proteins in metastatic non-small cell lung cancer (NSCLC) using formalin fixed paraffin embedded tissues, and have been validated for use in manual assays or with BioGenex automated staining systems.
The Programmed Cell Death ligand 1 (PD-L1) protein is upregulated in various cancers including many cases of NSCLC lung cancer. Binding of PD-L1 to PD1 cell surface receptors on cytotoxic T cells inhibit the antitumor immune response thus promoting tumor growth and metastasis. Lung cancer is by far the leading cause of cancer death and is responsible for about 1 out of every 4 cancer deaths in the United States. The American Cancer Society's estimates about 222,500 new cases of lung cancer and about 155,870 deaths from lung cancer in the US for 2017. 80-85% of lung cancers are classified as NSCLC and are relatively insensitive to chemotherapy. During the past three decades, lung cancer has shown the least improvement in survival rates when compared with other cancers.
"These antibodies add to BioGenex growing portfolio of cancer biomarkers product line and reflect our commitment to provide the most advanced solutions for tumor diagnosis, clinical and life science research. Our advanced systems which include automation, detection kits, antibodies, reagents, consumables and optimized protocols provide a fully integrated Workflow Solution for Pathology labs around the world," said BioGenex CEO, Dr. Krishan Kalra.
BioGenex offers over 400 antibodies for IHC. We are committed to continue to expand our molecular pathology product portfolio. Read more or call (800)-421-4149 to order.
About BioGenex: BioGenex designs, develops and commercializes molecular pathology systems for cancer diagnosis, prognosis, precession medicine and life science research. The recent introduction of our cytogenetic FISH workflow solution and miRNA system for characterization of Cancer of Unknown Primary (CUP) and undifferentiated tumors are a game changer and envy of the industry. Our fully-automated molecular pathology workstations are the most advanced system available globally. BioGenex prides itself on delivering cutting edge technology, years ahead of its competition, providing the finest systems for immunohistochemistry (IHC), In Situ hybridization (ISH), FISH, Special stains and in situ PCR. BioGenex unconditionally guarantees performance of its systems and products: antibodies, probes, antigen retrieval, detection systems and histology stains. We are committed to provide quality systems and best in class customer care.
Dr. Krishan Kalra, BioGenex Founder and CEO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biogenex-introduces-pd1-and-pdl-1-antibodies-for-immunohistochemistry-ihc-300420120.html